Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | MAOA | P21397 | 17/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1393082 | 1.00 | CYP3A4 (0.72) | CYP3A4CYP2C9CYP2D6MAOAMAOB | |
| SCHEMBL10267519 | 0.88 | MAOA (0.74) | CYP3A4CYP2C9CYP2D6MAOAMAOB | |
| SCHEMBL10197415 | 0.88 | MAOA (0.74) | CYP3A4CYP2C9CYP2D6MAOAMAOB | |
| SCHEMBL10197417 | 0.87 | MAOA (0.81) | CYP3A4CYP2C9CYP2D6MAOA | |
| SCHEMBL10261492 | 0.87 | MAOA (0.81) | CYP3A4CYP2C9CYP2D6MAOA | |
| SCHEMBL16789959 | 0.86 | MAOA (0.74) | CYP3A4CYP2C9CYP2D6MAOAMAOB | |
| SCHEMBL1394338 | 0.86 | CYP3A4 (0.69) | CYP3A4CYP2C9CYP2D6MAOAMAOB | |
| SCHEMBL1394340 | 0.86 | CYP3A4 (0.69) | CYP3A4CYP2C9CYP2D6MAOAMAOB | |
| SCHEMBL16093347 | 0.84 | MAOA (0.76) | CYP3A4CYP2C9CYP2D6MAOAMAOB | |
| SCHEMBL3328493 | 0.84 | CYP3A4 (0.79) | CYP3A4CYP2C9CYP2D6MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | MELINTA SUBSIDARY CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | MELINTA SUBSIDARY CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160136137-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | MELINTA SUBSIDIARY CORP. | 2016-05-19 | — | — | US | disclosed |
| US-20160136137-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | MELINTA SUBSIDIARY CORP. | 2016-05-19 | — | — | US | disclosed |
| US-20160136137-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | MELINTA SUBSIDIARY CORP. | 2016-05-19 | — | — | US | disclosed |
| WO-2016077818-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | MELINTA THERAPEUTICS, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20090118502-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-7456206-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456206-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7148219-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060264426-A1 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2006-11-23 | — | — | US | disclosed |
| EP-1660465-A2 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | Rib-X Pharmaceuticals, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-6969726-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-11-29 | — | — | US | disclosed |
| US-20050203147-A1 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-09-15 | — | — | US | disclosed |
| US-20050043317-A1 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-02-24 | — | — | US | disclosed |
| WO-2005012271-A2 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | RIB-X PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264426-A1 | Biaryl heterocyclic compounds and methods of making and using the same | PCNA, AADAC, MIF | CYP3A4 793/4885CYP2C9 1553/4885CYP2D6 304/4885 |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | CYP3A4 793/4885CYP2C9 1553/4885CYP2D6 304/4885 |
| US-20050043317-A1 | Biaryl heterocyclic compounds and methods of making and using the same | PCNA, AADAC, MIF | CYP3A4 793/4885CYP2C9 1553/4885CYP2D6 304/4885 |
| US-20090118502-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | CYP3A4 793/4885CYP2C9 1553/4885CYP2D6 304/4885 |
| US-20160136137-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | CUTA, CYP17A1, HSD17B11 | CYP3A4 957/4885CYP2C9 1333/4885CYP2D6 1856/4885 |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | CUTA, CYP17A1, HSD17B11 | CYP3A4 957/4885CYP2C9 1333/4885CYP2D6 1856/4885 |
| US-20050203147-A1 | Biaryl heterocyclic compounds and methods of making and using the same | PCNA, AADAC, MIF | CYP3A4 793/4885CYP2C9 1553/4885CYP2D6 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.